Advanced Proteome Therapeutics (STU:0E81) Cyclically Adjusted FCF per Share: €-0.02 (As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics Cyclically Adjusted FCF per Share?

Advanced Proteome Therapeutics STU:0E81 Cyclically Adjusted FCF per Share is €-0.02 as of Apr. 2023.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Advanced Proteome Therapeutics's adjusted free cash flow per share for the three months ended in Apr. 2023 was €-0.016. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.02 for the trailing ten years ended in Apr. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-25), Advanced Proteome Therapeutics's current stock price is €0.003. Advanced Proteome Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Apr. 2023 was €-0.02. Advanced Proteome Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Advanced Proteome Therapeutics  (STU:0E81) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Advanced Proteome Therapeutics Cyclically Adjusted FCF per Share Related Terms


Advanced Proteome Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Cyclically Adjusted FCF per Share Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.06 -0.05 -0.05 -0.04

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.04 -0.05 -0.05 -0.02

STU:0E81 vs VRTX, REGN, SGEN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Advanced Proteome Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Advanced Proteome Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Apr. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Apr. 2023 (Change)*Current CPI (Apr. 2023)
=-0.016/123.5712*123.5712
=-0.016

Current CPI (Apr. 2023) = 123.5712.

Advanced Proteome Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201307 -0.015 97.261 -0.019
201310 -0.016 97.182 -0.020
201401 -0.016 97.261 -0.020
201404 -0.013 98.920 -0.016
201407 -0.021 99.315 -0.026
201410 -0.025 99.473 -0.031
201501 -0.019 98.209 -0.024
201504 -0.021 99.710 -0.026
201507 -0.015 100.579 -0.018
201510 -0.016 100.500 -0.020
201601 -0.017 100.184 -0.021
201604 -0.014 101.370 -0.017
201607 -0.017 101.844 -0.021
201610 -0.007 102.002 -0.008
201701 -0.018 102.318 -0.022
201704 -0.014 103.029 -0.017
201707 -0.014 103.029 -0.017
201710 -0.018 103.424 -0.022
201801 -0.014 104.056 -0.017
201804 -0.022 105.320 -0.026
201807 -0.014 106.110 -0.016
201810 -0.010 105.952 -0.012
201901 -0.006 105.557 -0.007
201904 -0.009 107.453 -0.010
201907 -0.010 108.243 -0.011
201910 -0.004 107.927 -0.005
202001 -0.005 108.085 -0.006
202004 -0.007 107.216 -0.008
202007 -0.003 108.401 -0.003
202010 -0.003 108.638 -0.003
202101 -0.004 109.192 -0.005
202104 -0.005 110.851 -0.006
202107 -0.003 112.431 -0.003
202110 -0.003 113.695 -0.003
202201 -0.003 114.801 -0.003
202204 -0.011 118.357 -0.011
202207 -0.006 120.964 -0.006
202210 -0.006 121.517 -0.006
202301 -0.003 121.596 -0.003
202304 -0.016 123.571 -0.016

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.02 mean?
Advanced Proteome Therapeutics (STU:0E81) has a Cyclically Adjusted FCF per Share of €-0.02 as of Apr. 2023. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Cyclically Adjusted FCF per Share too high?
Advanced Proteome Therapeutics' current Cyclically Adjusted FCF per Share is €-0.02.
How does Advanced Proteome Therapeutics' Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Advanced Proteome Therapeutics' Cyclically Adjusted FCF per Share of €-0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current Cyclically Adjusted FCF per Share is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current Cyclically Adjusted FCF per Share of €-0.02. The current Cyclically Adjusted FCF per Share is €-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current Cyclically Adjusted FCF per Share is €-0.02 as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.